Description (Losartan Potassium Tablets Lupin 1)
Losartan Potassium
Product Images NDC 68645-526
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68645-526). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Legacy Pharmaceutical Packaging, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (Losartan Potassium Tablets Lupin 2)
The text seems to be showing results of a study labeled "Morihi." It includes data on two medications, Atenolol and Losartan, and their effect on reducing the primary endpoint in a sample of patients. The adjusted risk reduction percentage and p-value are provided. However, there is no available information on the nature of the primary endpoint or the characteristics of the patient sample.*
Figure 6 (Losartan Potassium Tablets Lupin 3)
This is a statistical chart displaying the percentage of patients who had fatal/non-fatal stroke while taking Atenolol versus Losartan. The chart also shows an adjusted risk reduction of 25% with Losartan with a p-value of 0.001. The text at the bottom appears to be a timeline marked in months.*
Figure 7 (Losartan Potassium Tablets Lupin 4)
The text appears to be a table showing the results of a study on the incidence of primary composite stroke (fatal/non-fatal) in patients with different demographics and medical histories. The table includes information on the number of events, hazard ratios, and rates for different patient characteristics such as age, race, and history of cardiovascular disease. The study also appears to compare the effectiveness of two different medications, Losartan and Atenolol, on the incidence of stroke. The figure included shows the primary endpoint events within demographic subgroups.*
Image 2 (Losartan Potassium Tablets Lupin 5)
This is a statistical analysis report on a sample of patients, where the risk reduction rate is 16.1% and the p-value obtained is 0.022. However, the meaning and context of the word "Menthe" is not clear from the given text.*
Losartan Potassium Tablets Usp 25mg (Losartan Potassium Tablets Lupin 6)
Losartan Potassium Tablets Usp 50mg (Losartan Potassium Tablets Lupin 7)
Losartan Potassium Tablets Usp 100mg (Losartan Potassium Tablets Lupin 8)
This is a description of Losartan Potassium Tablets, USP 100mg with NDC 68645-526-70. It is a prescription drug packaged in 30 tablets. The product is a film-coated tablet containing losartan potassium USP 100 mg. The product should be kept at 25°C (77°F), and the package should not be used if broken, blister card backing is torn, or individual blisters are open. The pharmacist should dispense this product with a patient information leaflet. Dosage information can be found in the accompanying prescribing information. The product is manufactured by Legacy Pharmaceutical Packaging, LLC. It is child-resistant and should not be separated from the protective carton. The product is intended for adults only. The instructions for opening the package are given on the package itself. It also has some color codes and other numbers that could indicate batch or manufacture information.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
